Asian Pacific Journal of Cancer Prevention

아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

New Gene Profiling in Determination of Breast Cancer Recurrence and Prognosis in Iranian Women

  • Poorhosseini, Seyed Mohammad (Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Hashemi, Mohammad (Department of Pathology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences) ;
  • Olyaei, Nasrin Alipour (Genomic Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Izadi, Amir (Young Researcher and Elite Club, Islamic Azad University) ;
  • Moslemi, Elham (Department of Biology, Islamic Azad University) ;
  • Ravesh, Zeinab (Genomic Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Hashemi-Gorji, Feyzollah (Genomic Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Kheiri, Hamid Reza (Department of Pharmaceutical Nanotechnology, School of Pharmacy) ;
  • Yassaee, Vahid Reza (Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences)
  • 발행 : 2016.06.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Breast cancer (BC) is the second most common cancer in the world and by far the most frequent cancer among women, with an estimated 1.67 million new cancer cases diagnosed in 2012 (25% of all cancers). Polygene expression analysis is used to predict the prognosis and determine the most appropriate treatment regimen. The objective of this study was to examine the gene expression profiles of SIRT3, HRAS, LSP1, SCUBE2 and AP2A2 in Iranian women with BC.A total of 136 patients including healthy controls were categorized into three groups based on the relapse of the disease. Expression of desired genes in formalin-fixed, paraffin embedded tissues collected from all groups of participants was analyzed via the RT PCR method. RNA extraction and cDNA synthesis were performed then real-time quantitative PCR was carried out. Gene expression analysis revealed that the expression of SIRT3 was equal among patient and control groups. LSP1 was down regulated in all patient groups relative to controls but reduced expression in the metastatic group relative to the non-metastatic one was not significant. HRAS was significantly overexpressed in total and metastatic tumor samples versus normal but not in non-metastatic cases. SCUBE2 expression showed significant over-expression in both overall tumor samples and the non-metastatic group as compared to normal tissues. Gene expression level of AP2A2 in all groups was not detectable. Our data are compatible with a tumor suppressor role of LSP1 related to potential prognostic factor for tumor recurrence and outcome. This study for the first time assayed the prognostic value and changes in the expression of SIRT3, LSP1, HRAS, SCUBE2 and AP2A2 genes in women with breast cancer in the Iranian population and findings confirmed potential biomarker and prognostic capability of these genes. Such expression profiling data can critically improve prognosis and treatment decisions in cancer patients.

키워드

참고문헌

  1. Antoniou AC, Sinilnikova OM, McGuffog L, et al (2009). Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet, 18, 4442-56. https://doi.org/10.1093/hmg/ddp372
  2. Ashraf N, Zino S, MacIntyre A, et al (2006). Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer, 95, 1056-61. https://doi.org/10.1038/sj.bjc.6603384
  3. Brennan DJ, Gallagher WM (2008). Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'. Breast Cancer Res, 10, 102. https://doi.org/10.1186/bcr1854
  4. Buroker NE, Huang J-Y, Barboza J, et al (2011). The adaptor-related protein complex 2, alpha 2 subunit ($AP2{\alpha}2$) gene is a peroxisome proliferator-activated receptor cardiac target gene. Protein J, 31, 75-83.
  5. Cancer CGoHFiB (2001). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. Lancet, 358, 1389-99. https://doi.org/10.1016/S0140-6736(01)06524-2
  6. Cancer CGoHFiB (2002). Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer, 87, 1234-45. https://doi.org/10.1038/sj.bjc.6600596
  7. Cheng CJ, Lin YC, Tsai MT, et al (2009). SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res, 69, 3634-41. https://doi.org/10.1158/0008-5472.CAN-08-3615
  8. Chou HL, Yao CT, Su SL, et al (2013). Gene expression profiling of breast cancer survivability by pooled cDNA microarray analysis using logistic regression, artificial neural networks and decision trees. BMC Bioinformatics, 14, 1-11. https://doi.org/10.1186/1471-2105-14-1
  9. Easton DF (2002). Familial risks of breast cancer. Breast Cancer Res, 4, 1-3. https://doi.org/10.1186/bcr464
  10. Easton DF, Pooley KA, Dunning AM, et al (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-93. https://doi.org/10.1038/nature05887
  11. Fan C, Oh DS, Wessels L, et al (2006). Concordance among Gene-Expression-Based Predictors for Breast Cancer. N Engl J Med, 355, 560-9. https://doi.org/10.1056/NEJMoa052933
  12. Fornaro L, Lonardi S, Masi G, et al (2013). FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol, 24, 2062-7. https://doi.org/10.1093/annonc/mdt165
  13. Giltnane JM, Balko JM (2014). Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med, 17, 275-83.
  14. Hannigan M, Zhan L, Ai Y, et al (2001). Leukocyte-specific gene 1 protein (LSP1) is involved in chemokine KC-activated cytoskeletal reorganization in murine neutrophils in vitro. J Leukoc Biol, 69, 497-504.
  15. Hirschey MD, Shimazu T, Goetzman E, et al (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature, 464, 121-5. https://doi.org/10.1038/nature08778
  16. Howard TH, Hartwig J, Cunningham C (1998). Lymphocyte-specific protein 1 expression in eukaryotic cells reproduces the morphologic and motile abnormality of NAD 47/89 neutrophils. Blood, 91, 4786-95.
  17. Irahara N, Baba Y, Nosho K, et al (2010). NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol, 19, 157-63. https://doi.org/10.1097/PDM.0b013e3181c93fd1
  18. Jiang Y, Shen H, Liu Xa, et al (2011). Genetic Variants at 1p11.2 and Breast Cancer Risk: A Two-Stage Study in Chinese Women. PLoS ONE, 6, e21563. https://doi.org/10.1371/journal.pone.0021563
  19. Kim HS, Patel K, Muldoon-Jacobs K, et al (2010). SIRT3 Is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during Stress. Cancer Cell, 17, 41-52. https://doi.org/10.1016/j.ccr.2009.11.023
  20. Kincaid B, Bossy-Wetzel E (2013). Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front Aging Neurosci, 5, 48.
  21. Li-Weber M (2013a). Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett, 332, 304-12. https://doi.org/10.1016/j.canlet.2010.07.015
  22. Li-Weber M (2013b). Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett, 332, 304-12. https://doi.org/10.1016/j.canlet.2010.07.015
  23. Lin Y-C, Chen C-C, Cheng C-J, et al (2011). Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J Biol Chem, 286, 27039-47. https://doi.org/10.1074/jbc.M111.244418
  24. Lin YC, Lee YC, Li LH, et al (2014). Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci, 127, 85-100. https://doi.org/10.1242/jcs.132779
  25. McKinney C, Fanciulli M, Merriman ME, et al (2010). Association of variation in $Fc{\gamma}$ receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples. Ann Rheum Dis, 69, 1711-6. https://doi.org/10.1136/ard.2009.123588
  26. Membrino A, Cogoi S, Pedersen EB, et al (2011). G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. PLoS ONE, 6, e24421. https://doi.org/10.1371/journal.pone.0024421
  27. Ozer E, Sis B, Ozen E, et al (2000). BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer: an immunohistochemical study. Appl Immunohistochem Mol Morphol, 8, 8-12.
  28. Patani N, Martin LA, Dowsett M (2013). Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer, 133, 1-13. https://doi.org/10.1002/ijc.27997
  29. Qiu X, Brown K, Hirschey MD, et al (2010). Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 Activation. Cell Metab, 12, 662-7. https://doi.org/10.1016/j.cmet.2010.11.015
  30. Saini KS, Loi S, de Azambuja E, et al (2013). Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev, 39, 935-46. https://doi.org/10.1016/j.ctrv.2013.03.009
  31. Schubbert S, Shannon K, Bollag G (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer, 7, 295-308. https://doi.org/10.1038/nrc2109
  32. Scorilas A, Levesque MA, Ashworth LK, et al (2002). Cloning, physical mapping and structural characterization of the human ${\alpha}A$-adaptin gene. Gene, 289, 191-9. https://doi.org/10.1016/S0378-1119(02)00504-8
  33. Shi T, Wang F, Stieren E, et al (2005). SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem, 280, 13560-7. https://doi.org/10.1074/jbc.M414670200
  34. Skrzypczak M, Lattrich C, Häring J, et al (2013). Expression of SCUBE2 gene declines in high grade endometrial cancer and associates with expression of steroid hormone receptors and tumor suppressor PTEN. Gynecol Endocrinol, 29, 1031-5. https://doi.org/10.3109/09513590.2013.829441
  35. Someya S, Yu W, Hallows WC, et al (2012). Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under Caloric restriction. Cell, 143, 802-12.
  36. Stacey SN, Manolescu A, Sulem P, et al (2007). Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet, 39, 865-9. https://doi.org/10.1038/ng2064
  37. Taghavi A, Fazeli Z, Vahedi M, et al (2012). Increased Trend of Breast Cancer Mortality in Iran. Asian Pac J Cancer Prev, 13, 367-70. https://doi.org/10.7314/APJCP.2012.13.1.367
  38. Tsai M-T, Cheng C-J, Lin Y-C, et al (2009). Isolation and characterization of a secreted, cell-surface glycoprotein SCUBE2 from humans. Biochem J, 422, 119-28. https://doi.org/10.1042/BJ20090341
  39. Vaziri H, Dessain SK, Eaton EN, et al (2001). em hSIR2 sup SIRT1 sup em Functions as an NAD-Dependent p53 Deacetylase. Cell, 107, 149-59. https://doi.org/10.1016/S0092-8674(01)00527-X
  40. Yang R-B, Ng CKD, Wasserman SM, et al (2002). Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J BiolChem, 277, 46364-73.
  41. Young A, Lou D, McCormick F (2013). Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov, 3, 112-23.